Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 15 2023 - 7:30AM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a clinical-stage biopharmaceutical company developing novel
treatments for solid tumors, with a primary focus on female
cancers, today announced that an abstract regarding Context’s
preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific
antibody, has been selected for poster presentation at the American
Association for Cancer Research (AACR) Annual Meeting 2023, taking
place April 14-19, 2023, at the Orange County Convention Center in
Orlando, FL.
Details of the presentation are as follows:
Title: Development of CTIM-76, a highly specific Claudin 6
bispecific antibody for treatment of ovarian cancerSession
Category: ImmunologySession: PO.IM01.18 - Therapeutic Antibodies
1Abstract Number: 1865 / 4Presenter: Joseph Rucker, Ph.D., Integral
MolecularDate and Time: April 17, 2023, 9:00 a.m. - 12:30 p.m.
ETLocation: Section 25
For more information and to view the abstract, visit the AACR
Annual Meeting website.
On Monday, April 17, 2023, at 4:30 p.m. ET, Context will host a
webinar with its management team and AACR presenter, Dr. Rucker, to
discuss the results from this presentation and provide updates on
the CTIM-76 preclinical program. Following the formal presentation,
the Context team, along with Dr. Rucker, will be available for
questions. To register for the webinar, please click here.
Additionally, a replay of the webinar will be available on the
Events page of the Investor Relations section of Context’s
website, www.contexttherapeutics.com, for approximately 30
days after the webinar.
About Claudin 6 and CTIM-76Claudin 6
(CLDN6) is differentially expressed on cancer cells with no or
very low expression in normal, healthy tissue. CLDN6-enriched
cancers include ovarian, endometrial, testicular, and gastric,
among others. With the potential to reach a large patient
population and selective expression on cancer cells, CLDN6 has
emerged as an important drug target.
CTIM-76 is a CLDN6 and CD3 bispecific antibody currently in
preclinical development that is capable of binding to tumor cells
expressing CLDN6 and stimulating intra-tumoral T cells by the CD3
arm that is designed to be activated only upon tumor engagement
while silent elsewhere. CLDN6 is expressed on multiple solid tumors
such as ovarian cancer, sarcoma, testicular cancer, endometrial
cancer, and gastric cancer. Preclinical studies of CTIM-76 show it
effectively maintains a strong tumor binding property and
anti-tumor activity attributable to a synergistic effect of both
CLDN6 antibody and CD3 antibody while avoiding systemic
immunotoxicity commonly seen with CD3 antibodies as a drug class.
CTIM-76 has the potential for convenient dosing and scalable
manufacturing to address the significant number of patients who are
potentially eligible for CTIM-76 therapy.
About Context Therapeutics®Context Therapeutics
Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical
company committed to advancing medicines for solid tumors, with a
primary focus on female cancers. The Company’s pipeline includes
small molecule and bispecific antibody drug candidates that target
cancer signaling pathways. Context is developing CTIM-76, a
selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6
positive tumors, currently in preclinical development. Context is
also developing onapristone extended release (ONA-XR), a novel,
first-in-class potent and selective progesterone receptor
antagonist. Context is headquartered in Philadelphia. For more
information, please visit www.contexttherapeutics.com or
follow the Company on Twitter and LinkedIn.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the ability of the Company, its employees
and certain AACR presenters to participate in and present at
conferences and webinars, (ii) the timing, enrollment and results
of our clinical trials, (iii) the potential benefits and side
effect profile of our product candidates, (iv) the likelihood data
will support future development, and (v) the likelihood of
obtaining regulatory approval of our product candidates.
Forward-looking statements in this release involve substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by the forward-looking
statements, and we, therefore cannot assure you that our plans,
intentions, expectations or strategies will be attained or
achieved. Other factors that may cause actual results to differ
from those expressed or implied in the forward-looking statements
in this press release are discussed in our filings with
the U.S. Securities and Exchange Commission, including the
section titled “Risk Factors” contained therein. Except as
otherwise required by law, we disclaim any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine YonkerEdison
Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Apr 2024 to May 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From May 2023 to May 2024